In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers^[1] for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

But the price of these injections is steep: They cost about US$800-$1,000 per month^[2], and if used for weight loss alone, they are not covered by most insurance policies^[3]. Both...

The Drug Enforcement Administration announced in early 2024 that it would act on President Joe Biden’s call to reclassify marijuana^[1], moving it from the tightly controlled Schedule I category^[2] that it has been in since 1970 to the less restrictive Schedule III status of the Controlled Substances Act. That triggered a long process^[3] of hearings and reviews that will not be completed until after the presidential election...